Davide Zecchin
Overview
Explore the profile of Davide Zecchin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
2614
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bryant D, Barberan-Martin S, Maeshima R, Del Valle Torres I, Rabii M, Baird W, et al.
J Invest Dermatol
. 2024 Jun;
145(1):122-134.e11.
PMID: 38897541
RAS proteins regulate cell division, differentiation, and apoptosis through multiple downstream effector pathways. Oncogenic RAS variants are the commonest drivers in cancers; however, they also drive many benign lesions predisposing...
2.
Knopfel N, Zecchin D, Richardson H, Polubothu S, Barberan-Martin S, Cullup T, et al.
J Invest Dermatol
. 2023 Oct;
144(4):820-832.e9.
PMID: 37802294
Mosaic mutations in genes GNAQ or GNA11 lead to a spectrum of diseases including Sturge-Weber syndrome and phakomatosis pigmentovascularis with dermal melanocytosis. The pathognomonic finding of localized "tramlining" on plain...
3.
Zecchin D, Knopfel N, Gluck A, Stevenson M, Sauvadet A, Polubothu S, et al.
J Invest Dermatol
. 2023 Oct;
144(4):811-819.e4.
PMID: 37802293
Mosaic variants in genes GNAQ or GNA11 lead to a spectrum of vascular and pigmentary diseases including Sturge-Weber syndrome, in which progressive postnatal neurological deterioration led us to seek biologically...
4.
Martin S, Polubothu S, Bruzos A, Kelly G, Horswell S, Sauvadet A, et al.
J Invest Dermatol
. 2023 Sep;
144(3):593-600.e7.
PMID: 37716647
Among children with multiple congenital melanocytic nevi, 25% have no established genetic cause, of whom many develop a hyperproliferative and severely pruritic phenotype resistant to treatment. Gene fusions have been...
5.
Polubothu S, Bender N, Muthiah S, Zecchin D, Demetriou C, Martin S, et al.
J Invest Dermatol
. 2022 Dec;
143(6):1042-1051.e3.
PMID: 36566878
Phakomatosis pigmentovascularis is a diagnosis that denotes the coexistence of pigmentary and vascular birthmarks of specific types, accompanied by variable multisystem involvement, including CNS disease, asymmetrical growth, and a predisposition...
6.
Polubothu S, Zecchin D, Al-Olabi L, Lionarons D, Harland M, Horswell S, et al.
Genet Med
. 2021 Jun;
23(9):1636-1647.
PMID: 34145395
Purpose: Much of the heredity of melanoma remains unexplained. We sought predisposing germline copy-number variants using a rare disease approach. Methods: Whole-genome copy-number findings in patients with melanoma predisposition syndrome...
7.
Zecchin D, Moore C, Michailidis F, Horswell S, Rana S, Howell M, et al.
EMBO Mol Med
. 2020 Jul;
12(8):e11987.
PMID: 32672423
Triple-negative breast cancer (TNBC) has poorer prognosis compared to other types of breast cancers due to the lack of effective therapies and markers for patient stratification. Loss of PTEN tumor...
8.
Coelho M, de Carne Trecesson S, Rana S, Zecchin D, Moore C, Molina-Arcas M, et al.
Immunity
. 2017 Dec;
47(6):1083-1099.e6.
PMID: 29246442
The immunosuppressive protein PD-L1 is upregulated in many cancers and contributes to evasion of the host immune system. The relative importance of the tumor microenvironment and cancer cell-intrinsic signaling in...
9.
Olivero M, Dettori D, Arena S, Zecchin D, Lantelme E, Di Renzo M
Oncotarget
. 2014 Aug;
5(15):5992-6002.
PMID: 25115388
CDT2/L2DTL/RAMP is one of the substrate receptors of the Cullin Ring Ubiquitin Ligase 4 that targets for ubiquitin mediated degradation a number of substrates, such as CDT1, p21 and CHK1,...
10.
Sun C, Hobor S, Bertotti A, Zecchin D, Huang S, Galimi F, et al.
Cell Rep
. 2014 Apr;
7(1):86-93.
PMID: 24685132
There are no effective therapies for the ~30% of human malignancies with mutant RAS oncogenes. Using a kinome-centered synthetic lethality screen, we find that suppression of the ERBB3 receptor tyrosine...